Under the gun, Nymox sparks another rally with a new batch of follow-up BPH data
More than a year ago, Nymox Pharmaceutical managed to whip up a big rally for its battered stock $NYMX after claiming an unexpected turnaround for its lead drug fexapotide for treating an enlarged prostate. A pair of late-stage failures — which shredded its stock — had been overcome with positive data from an extension of the trial, execs said.
The next step, company CEO Paul Averback assured investors, would be to trek to regulators for a discussion about filing for an approval on the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.